Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs Loom by Year-End
Becton Dickinson and Co. (NYSE: BDX ) plans to invest $3 billion in U.S. medical-product manufacturing, President Donald Trump said. In a Truth Social post late Monday, Trump said that more than $1 billion will be invested in Nebraska, where BD plans to expand medical-product production, including needles made from U.S. steel. The President said that the investment was tied to planned “strong” medical device tariffs expected by year-end. Trump said the domestic expansion would boost production of syringes, needles, lab kits and other medical products. Notably, the Trump administration weighs potential tariffs on imported medical devices following a Commerce Department Section 232 investigation launched in September 2025. The department had 270 days to submit its findings to the President; however, a public final report or tariff decision is yet to be announced. In January, the company said it plans to invest $110 million to expand prefillable syringe production at its Columbus, Nebraska, plant, creating about 120 jobs, following an earlier $35 million investment at the site. Becton Dickinson did not immediately respond to ’s request for comments. Read Also: JD Vance Hails Trump’s R
Becton Dickinson and Co. S. medical-product manufacturing, President Donald Trump said. S.
steel. The President said that the investment was tied to planned “strong” medical device tariffs expected by year-end. Trump said the domestic expansion would boost production of syringes, needles, lab kits and other medical products. Notably, the Trump administration weighs potential tariffs on imported medical devices following a Commerce Department Section 232 investigation launched in September 2025.
The department had 270 days to submit its findings to the President; however, a public final report or tariff decision is yet to be announced. In January, the company said it plans to invest $110 million to expand prefillable syringe production at its Columbus, Nebraska, plant, creating about 120 jobs, following an earlier $35 million investment at the site. Becton Dickinson did not immediately respond to ’s request for comments.
Read Also: JD Vance Hails Trump’s Red-Dyed Diesel Order to Tackle High Fuel Prices, but Top Oil Analyst Warns It May Not Lower Costs: 'Limited and Uneven' BD Streamlines Portfolio Earlier this year, BD completed the spin-off of its Biosciences & Diagnostic Solutions business and its combination with Waters Corporation, marking the final step of its BD 2025 strategy. CEO Tom Polen had said the move leaves BD as a focused pure-play MedTech company, following the divestiture of three non-core assets and more than 20 strategic acquisitions. 23.
The company raised the midpoint of its adjusted EPS outlook and expects full-year revenue growth toward the high end of its guidance range, citing continued momentum and margin improvement. S. He credited his 50% tariffs on steel imports with driving investment and reviving the domestic steel industry. S.
history. S. S. tariffs on South Korean imports to 15% from 25%.
S. LNG and other energy products. 74% to $182 premarket on Tuesday. Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published editors.
Read Also: Trump Says Democrats Could Bring a 1929-Style Depression — Peter Schiff Says It May Happen Either Way: 'Forecast Enables Him to Blame Congress' Image via Shutterstock